Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

123I-BMIPP SPECT Analysis for Decreasing Cardiac Events in Hemodialysis Patients (B-SAFE)

This study has been completed.
Toho University Ohashi Medical Center
Information provided by:
Translational Research Informatics Center, Kobe, Hyogo, Japan Identifier:
First received: December 21, 2007
Last updated: September 12, 2011
Last verified: February 2009
The aim of this multi-center study is to determine the applicability of BMIPP to diagnosing cardiac disease and to predicting the outcome of patients on hemodialysis.

Coronary Disease
Fatty Acids, Unsaturated
Single Photon Emission Computed Tomography

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Outcome Study on BMIPP SPECT Analysis for Decreasing Cardiac Events in Hemodialysis Patients

Resource links provided by NLM:

Further study details as provided by Translational Research Informatics Center, Kobe, Hyogo, Japan:

Estimated Enrollment: 1000
Study Start Date: June 2006
Study Completion Date: September 2011
Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Defined Population

Inclusion Criteria:Adult hemodialysis patients with one or more of the following 10 risk factors for coronary heart disease

  • Hypertension
  • Diabetes mellitus
  • Hyperlipidemia
  • Obliterative arteriosclerosis in the lower extremities
  • Smoker
  • Family history of juvenile coronary artery disease
  • History of ischemic stroke
  • History of heart failure requiring hospitalization
  • Within 3 months after initiation of hemodialysis therapy
  • Dialysis hypotension

Exclusion Criteria:Hemodialysis patients who meet any one of the following conditions will be excluded.

  • Peritoneal dialysis
  • Severe valvular disorder requiring treatment
  • Diagnosis of hypertrophic cardiomyopathy(HCM) or dilated cardiomyopathy(DCM) before start of dialysis
  • History of revascularization(PCI, CABG) or prior diagnosis of myocardial infarction
  • Hypersensitivity to BMIPP or its analogue
  • Judged unsuitable for the study for any other reasons by physicians.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00586950

Toho University Ohashi Medical Center
Meguro-ku, Tokyo, Japan, 135-8515
Sponsors and Collaborators
Translational Research Informatics Center, Kobe, Hyogo, Japan
Toho University Ohashi Medical Center
Principal Investigator: Kenjiro Kikuchi, MD, PhD Asahikawa Medical College
  More Information

Responsible Party: Kenjiro Kikuchi, MD, PhD , Principal Investigator, Hokkaido Cardiovascular Hospital Identifier: NCT00586950     History of Changes
Other Study ID Numbers: UHA_CAD05-01
Study First Received: December 21, 2007
Last Updated: September 12, 2011

Keywords provided by Translational Research Informatics Center, Kobe, Hyogo, Japan:
Myocardial Free Fatty Acid metabolism
High risk patients
End-stage renal failure
Cardiovascular events

Additional relevant MeSH terms:
Coronary Disease
Coronary Artery Disease
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Arterial Occlusive Diseases processed this record on May 24, 2017